Analyst Report: ABT

1. EXECUTIVE SUMMARY

Abbott Laboratories (NYSE: ABT) experienced a major bullish breakout, surging 12.84% over the weekly period ending July 21, 2026, to close at $99.67 (touching intraday highs of $101.87). The surge was driven by Abbott’s Q2 2026 earnings release on July 16, 2026, where the company delivered a beat on top- and bottom-line estimates and raised its full-year 2026 adjusted earnings per share (EPS) guidance. Revenue jumped 13.0% reported (4.8% comparable) to $12.593 billion, anchored by an 8.4% comparable expansion in Medical Devices and mid-teens growth in Cancer Diagnostics following the successful integration of Exact Sciences. With adjusted gross margins expanding 107 basis points to 58.0% and legal overhangs dissipating, the move marks a fundamental trend reversal after multi-month selling pressure, positioning Abbott for sustained momentum heading into the second half of fiscal year 2026.

2. THE CATALYST (CRITICAL)

The catalyst behind the 12.84% weekly surge was the release of Abbott’s Q2 2026 Financial Results before market open on Thursday, July 16, 2026.

Key Performance Highlights vs. Wall Street Expectations:

• Adjusted EPS Beat: Abbott reported Q2 2026 adjusted diluted EPS of $1.31, beating Wall Street consensus estimates of $1.28 by $0.03 (+2.3% surprise). GAAP diluted EPS came in at $0.53.
• Revenue Beat: Total net sales reached $12.593 billion (+13.0% reported YoY, +4.8% comparable), surpassing consensus expectations of $12.50 billion.
• Guidance Upgrade: Management raised its full-year 2026 adjusted diluted EPS guidance to $5.45 – $5.60 (up from the prior guidance range of $5.38 – $5.58), representing a $0.05 increase at the midpoint. Full-year comparable sales growth guidance was reaffirmed at 6.5% – 7.5%.
• Segment Breakdown:
  • Medical Devices: Revenue grew to $5.853 billion (+8.4% comparable), powered by double-digit growth in Electrophysiology, Diabetes Care (FreeStyle Libre), Rhythm Management, and Heart Failure franchises.
  • Cancer Diagnostics & Exact Sciences Integration: Diagnostics sales reached $3.092 billion. Cologuard screening and cancer diagnostics grew in the mid-teens, validating the strategic acquisition of Exact Sciences closed on March 23, 2026.
  • Established Pharmaceuticals (EPD): Comparable sales grew 8.7% YoY, driven by durable demand across emerging markets.
  • Nutrition: Net sales were $2.08 billion (-3.6% comparable YoY), but rebounded sequentially by +$127 million compared to Q1 2026.

Source Date: Press release published via PR Newswire & SEC Form 8-K filed July 16, 2026.

3. COMPANY PROFILE

Core Business

Abbott Laboratories (NYSE: ABT) is a global healthcare giant headquartered in Abbott Park, Illinois. Founded in 1888, Abbott operates four primary business units:

1. Medical Devices: Cardiovascular tools, structural heart products, electrophysiology, neuromodulation, and diabetes care devices (including market-leading FreeStyle Libre continuous glucose monitors).
2. Diagnostics: Core laboratory systems, point-of-care testing, rapid diagnostics, and cancer screening platforms.
3. Established Pharmaceuticals: High-quality, branded generic medicines sold in high-growth emerging international markets.
4. Nutrition: Science-based pediatric and adult nutritional products (e.g., Similac, Ensure, Pedialyte).

4. DEEP DIVE ANALYSIS

Fundamentals vs. Market Overreaction

The +12.84% weekly surge was a justified structural repricing rather than a temporary overreaction. Heading into July 2026, ABT shares were heavily depressed (trading near $88–$89) due to three macro overhangs:

1. Concerns over volume headwinds in pediatric nutrition.
2. Continuous glucose monitor (CGM) competitive anxiety and recall publicity regarding Libre 3 sensors.
3. DOJ regulatory scrutiny into legacy infant formula issues.

Q2 results systematically addressed each worry:

• Margin Expansion: Adjusted gross margins expanded 107 bps YoY to 58.0%, illustrating that cost inflation is abating and higher-margin MedTech/Diagnostics products are driving top-line expansion.
• M&A Accretion: The integration of Exact Sciences (acquired March 23, 2026) added a high-growth cancer screening arm (Cologuard), contributing directly to the mid-teens growth in Cancer Diagnostics.
• Legal De-Risking: News broke during mid-July that the U.S. DOJ closed its criminal investigation into Abbott’s baby formula facilities without filing criminal charges, lifting a dark cloud off the stock.

                     Q2 2026 Performance Highlights
  +-----------------------+-----------------------+-----------------------+
  |  Revenue Beat         |  Adjusted EPS Beat    |  FY EPS Guidance      |
  |  $12.593B (+13.0%)      |  $1.31 vs $1.28 Est.  |  $5.45–$5.60 (Raised) |
  +-----------------------+-----------------------+-----------------------+

Peer & Sector Context

While broader MedTech peers have struggled in 2026 with procedure volume uncertainty and hospital capital budget constraints, Abbott's Medical Device division (+8.4% comparable sales growth) demonstrated superior resilient growth. Electrophysiology and structural heart procedures remained at elevated levels, outpacing direct competitors like Medtronic and Boston Scientific in key sub-segments.

Bull Case vs. Bear Case

• Bull Case:

  • Pipeline Catalysts: CE Mark secured for Libre Duo (dual glucose-ketone sensor), enrollment completed for the TECTONIC U.S. pivotal trial (Coronary IVL), and FDA submission of the Amulet 360 LAA closure device.
  • Diagnostics Monetization: Strategic licensing agreement with ALZpath for pTau217 blood-based testing for Alzheimer's disease on the Alinity platform, creating a multi-year growth runway.
  • Aristocrat Security: 51 consecutive years of dividend increases backed by $2.29B in quarterly net earnings excluding specified items.

• Bear Case:

  • Nutrition Drag: Worldwide Nutrition sales dropped 3.6% on a comparable basis due to pricing adjustments and volume headwinds.
  • GLP-1 Pressure: Long-term market sentiment around GLP-1 weight-loss drugs suppressing nutritional product volumes.
  • Integration & Debt Costs: Dilution and execution risk associated with absorbing Exact Sciences and related debt service in a high-rate environment.

5. TECHNICAL SNAPSHOT

On July 16, 2026, ABT staged an aggressive high-volume breakout, rising from $89.27 to $98.83 (+10.71%) on the day of earnings, before consolidating in the $99.60–$101.80 zone through July 21.

Price ($)
105.00 |                                    [Resistance: $102.00–$105.00]
102.00 |                           * Intraday High ($101.87)
100.00 |                     * * * * Close ($99.67 - July 21)
 95.00 |                   /
 90.00 |         * * * * *  <- Post-Earnings Gap Up (July 16)
 85.00 | * * * *            [Support: $88.00–$90.00]
       +------------------------------------------------------------> Time
         Early July         July 16 (Earnings)     July 21, 2026

• Volume Analysis: Trading volume on July 16 spiked to 32.76 million shares—more than 3x average daily volume (~10 million shares). High volume on an upward gap confirms aggressive institutional buying and short covering.
• Key Support Levels:
  • Immediate Support: $98.30 – $98.80 (July 16 closing price and intraday consolidation base).
  • Major Support: $94.50 – $95.00 (gap-fill boundary).
• Key Resistance Levels:
  • Immediate Resistance: $101.87 – $102.50 (July 16 intraday peak).
  • Major Resistance: $105.80 – $112.00 (200-day moving average and analyst consensus targets).

6. RISK FACTORS

1. Litigation Settlement Costs: Ongoing civil litigation regarding necrotizing enterocolitis (NEC) claims against preterm infant formulas, as well as False Claims Act settlements.
2. Nutrition Segment Weakness: Failure of the Nutrition business to achieve positive growth in Q3/Q4 could constrain overall corporate revenue growth.
3. Competitive CGM Pricing: Intense competition from DexCom's non-prescription CGMs (Stelo) and Next-Gen G7 features threatening FreeStyle Libre market share.
4. Integration Milestones: Delayed realization of revenue synergies from the Exact Sciences platform.

7. ACTIONABLE OUTLOOK